HROW
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Harrow announced patient-reported data on discomfort following intravitreal injections with IHEEZOAug 20, 2026
- Harrow acquired global rights to TYRVAYA, the first FDA-approved nasal spray for dry eye diseaseAug 6, 2026
- Harrow launched BYOOVIZ commercially in the United StatesJul 1, 2026
- Harrow re-launched VERKAZIA for vernal keratoconjunctivitis in pediatric patientsJun 10, 2026
- Harrow announced plans to initiate a Phase 3 trial to expand the TRIESENCE label to include ocular inflammation and pain following cataract surgeryMar 3, 2026